Catalysts for Darzalex Faspro
16 tracked
Apr 29, 2026
phase 2 initiation
National Cancer Institute US — (daratumumab + hyaluronidase (human recombinant)) (Phase II Trial Initiation)
(daratumumab + hyaluronidase (human recombinant))
→
Feb 12, 2026
approval
DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval
(daratumumab + hyaluronidase (human recombinant))
→
Jan 27, 2026
approval
DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval
(daratumumab + hyaluronidase (human recombinant))
→
Nov 19, 2025
approval
DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval
(daratumumab + hyaluronidase (human recombinant))
→
Nov 14, 2025
approval
DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval
(daratumumab + hyaluronidase (human recombinant))
→
Nov 6, 2025
approval
DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval
(daratumumab + hyaluronidase (human recombinant))
→
Jul 30, 2024
approval
DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval
(daratumumab + hyaluronidase (human recombinant))
→
Nov 2, 2022
approval
DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval
(daratumumab + hyaluronidase (human recombinant))
→
Jan 21, 2022
approval
DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval
(daratumumab + hyaluronidase (human recombinant))
→
Nov 30, 2021
approval
DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval
(daratumumab + hyaluronidase (human recombinant))
→
Jul 9, 2021
approval
DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval
(daratumumab + hyaluronidase (human recombinant))
→
Mar 12, 2021
approval
DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval
(daratumumab + hyaluronidase (human recombinant))
→
Feb 8, 2021
approval
DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval
(daratumumab + hyaluronidase (human recombinant))
→
Jan 15, 2021
approval
DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval
(daratumumab + hyaluronidase (human recombinant))
→
Jan 11, 2021
approval
DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval
(daratumumab + hyaluronidase (human recombinant))
→
May 1, 2020
approval
DARZALEX FASPRO (DARATUMUMAB AND HYALURONIDASE-FIHJ) — FDA approval
(daratumumab + hyaluronidase (human recombinant))
→